Vascular Deletion of HDAC6 Ameliorates Diabetic Retinal Microangiopathy and Diabetic Retinopathy in an Experimental Model of Type 1 Diabetes
Cells · 10.07.2026 · 15 (14) · 1244
DOI: 10.3390/cells15141244 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 10.07.2026. Verfasst von Sheila Ngumbi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Histone Deacetylase 6, Diabetes Mellitus, Type 1, Diabetes Mellitus, Experimental. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, NIH-RO1, NIH.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Diabetic retinopathy (DR) is a leading cause of vision loss among working-age adults and is characterized by progressive retinal microvascular dysfunction driven by hyperglycemia-induced inflammation and oxidative stress. Histone deacetylase 6 (HDAC6), a cytoplasmic deacetylase involved in multiple cellular processes, has been implicated in vascular pathology; however, its specific role in retinal endothelial cells remains unclear. In this study, we investigated whether endothelial-specific deletion of HDAC6 protects against diabetic retinal injury. Endothelial HDAC6 knockout mice were generated using VE-cadherin–Cre recombination and subjected to streptozotocin-induced diabetes. Retinal vascular integrity, inflammatory and oxidative stress responses, endothelial senescence, and visual function were assessed during the course of hyperglycemia. Diabetic control mice developed characteristic features of DR, including vascular dysfunction, heightened inflammatory and oxidative stress responses, increased endothelial senescence, and impaired visual function. In contrast, endothelial-specific HDAC6 deletion markedly attenuated these pathological changes, preserving retinal vascular integrity and visual performance while reducing oxidative stress and inflammation. These findings identify endothelial HDAC6 as a key contributor to diabetes-induced retinal vascular injury and suggest that targeting endothelial HDAC6 may represent a promising therapeutic strategy for preventing microvascular damage and vision loss in DR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
- Department of Medical Histology and Cell Biology, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
- Immunology Center of Georgia, Augusta University, Augusta, GA 30912, USA.
ORCID-Profile: Mohamed S Gad, Adil Ijaz
Förderung
- NEI NIH HHS
- NIH-RO1
- NIH
Zitieren
APA
Ngumbi, S., Gad, M. S., Mahrous, M., Ijaz, A., Orecchioni, M., Bollinger, K., & Bartoli, M. (2026). Vascular Deletion of HDAC6 Ameliorates Diabetic Retinal Microangiopathy and Diabetic Retinopathy in an Experimental Model of Type 1 Diabetes. Cells, 15(14), 1244. https://doi.org/10.3390/cells15141244
Vancouver
Ngumbi S, Gad MS, Mahrous M, Ijaz A, Orecchioni M, Bollinger K, et al. Vascular Deletion of HDAC6 Ameliorates Diabetic Retinal Microangiopathy and Diabetic Retinopathy in an Experimental Model of Type 1 Diabetes. Cells. 2026;15(14):1244. doi:10.3390/cells15141244
BibTeX
@article{Ngumbi2026,
author = {Ngumbi, Sheila and Gad, Mohamed S and Mahrous, Mostafa and Ijaz, Adil and Orecchioni, Marco and Bollinger, Kathryn and Bartoli, Manuela},
title = {Vascular Deletion of HDAC6 Ameliorates Diabetic Retinal Microangiopathy and Diabetic Retinopathy in an Experimental Model of Type 1 Diabetes},
journal = {Cells},
year = {2026},
volume = {15},
number = {14},
pages = {1244},
doi = {10.3390/cells15141244}
}
EUVIMED